WO2000010554A3 - Procedes et compositions employant le vigabatrin s(+) optiquement pur - Google Patents
Procedes et compositions employant le vigabatrin s(+) optiquement pur Download PDFInfo
- Publication number
- WO2000010554A3 WO2000010554A3 PCT/US1999/019346 US9919346W WO0010554A3 WO 2000010554 A3 WO2000010554 A3 WO 2000010554A3 US 9919346 W US9919346 W US 9919346W WO 0010554 A3 WO0010554 A3 WO 0010554A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vigabatrin
- methods
- optically pure
- compositions employing
- employing optically
- Prior art date
Links
- PJDFLNIOAUIZSL-RXMQYKEDSA-N (4s)-4-azaniumylhex-5-enoate Chemical compound C=C[C@@H](N)CCC(O)=O PJDFLNIOAUIZSL-RXMQYKEDSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000029650 alcohol withdrawal Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000565876A JP2003520189A (ja) | 1998-08-25 | 1999-08-24 | 光学的に純粋なs(+)ビガバトリンを用いる方法および組成物 |
CA002341400A CA2341400A1 (fr) | 1998-08-25 | 1999-08-24 | Procedes et compositions employant le vigabatrin s(+) optiquement pur |
AU57844/99A AU5784499A (en) | 1998-08-25 | 1999-08-24 | Methods and compositions employing optically pure s(+) vigabatrin |
EP99945177A EP1107748A2 (fr) | 1998-08-25 | 1999-08-24 | Procedes et compositions employant le vigabatrin s(+) optiquement pur |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9778698P | 1998-08-25 | 1998-08-25 | |
US60/097,786 | 1998-08-25 | ||
US11445698P | 1998-12-30 | 1998-12-30 | |
US60/114,456 | 1998-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000010554A2 WO2000010554A2 (fr) | 2000-03-02 |
WO2000010554A3 true WO2000010554A3 (fr) | 2000-11-30 |
Family
ID=26793638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/019346 WO2000010554A2 (fr) | 1998-08-25 | 1999-08-24 | Procedes et compositions employant le vigabatrin s(+) optiquement pur |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1107748A2 (fr) |
JP (1) | JP2003520189A (fr) |
AU (1) | AU5784499A (fr) |
CA (1) | CA2341400A1 (fr) |
WO (1) | WO2000010554A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100179214A1 (en) | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
US20100179215A1 (en) | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
US20080058408A1 (en) | 2006-05-19 | 2008-03-06 | Rogowski Roberta L | Low-dose doxepin for treatment of sleep disorders in elderly patients |
JP2009537553A (ja) | 2006-05-19 | 2009-10-29 | ソマクソン ファーマシューティカルズ インコーポレイテッド | 睡眠改善のための低用量ドキセピンの使用法 |
WO2008011150A1 (fr) | 2006-07-20 | 2008-01-24 | Somaxon Pharmaceuticals, Inc. | Méthodes destinées à améliorer la pharmacocinétique de la doxépine |
WO2008052139A2 (fr) | 2006-10-25 | 2008-05-02 | Somaxon Pharmaceuticals, Inc. | Doxepine à dose ultrafaible, et ses procédés d'utilisation pour traiter des troubles du sommeil |
US20110077200A1 (en) | 2006-12-06 | 2011-03-31 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
US20090074862A1 (en) | 2007-04-13 | 2009-03-19 | Luigi Schioppi | Low-dose doxepin formulations and methods of making and using the same |
CA3016851A1 (fr) * | 2016-03-10 | 2017-09-14 | Orphelia Pharma | Formes galeniques solides de vigabatrine |
CN110869003A (zh) * | 2019-01-28 | 2020-03-06 | 上海奥科达生物医药科技有限公司 | 一种不含防腐剂的固体剂型氨己烯酸药物组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595697A (en) * | 1984-03-28 | 1986-06-17 | Merrell Dow Pharmaceuticals Inc. | Treatment of seizure disorders and pharmaceutical compositions useful therein |
US4621145A (en) * | 1982-12-30 | 1986-11-04 | Merrell Dow Pharmaceuticals Inc. | Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor |
EP0509180A1 (fr) * | 1991-04-18 | 1992-10-21 | Merrell Dow Pharmaceuticals Inc. | Utilisation d'inhibiteurs de la GABA-T pour le traitement de la schizophrenie et l'intoxication de la phencyclidine |
WO2000007583A2 (fr) * | 1998-08-05 | 2000-02-17 | Brookhaven Science Associates | Traitement de l'accoutumance et comportement lie a l'accoutumance |
-
1999
- 1999-08-24 WO PCT/US1999/019346 patent/WO2000010554A2/fr not_active Application Discontinuation
- 1999-08-24 CA CA002341400A patent/CA2341400A1/fr not_active Abandoned
- 1999-08-24 JP JP2000565876A patent/JP2003520189A/ja active Pending
- 1999-08-24 AU AU57844/99A patent/AU5784499A/en not_active Abandoned
- 1999-08-24 EP EP99945177A patent/EP1107748A2/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4621145A (en) * | 1982-12-30 | 1986-11-04 | Merrell Dow Pharmaceuticals Inc. | Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor |
US4595697A (en) * | 1984-03-28 | 1986-06-17 | Merrell Dow Pharmaceuticals Inc. | Treatment of seizure disorders and pharmaceutical compositions useful therein |
EP0509180A1 (fr) * | 1991-04-18 | 1992-10-21 | Merrell Dow Pharmaceuticals Inc. | Utilisation d'inhibiteurs de la GABA-T pour le traitement de la schizophrenie et l'intoxication de la phencyclidine |
WO2000007583A2 (fr) * | 1998-08-05 | 2000-02-17 | Brookhaven Science Associates | Traitement de l'accoutumance et comportement lie a l'accoutumance |
Non-Patent Citations (10)
Title |
---|
ALVES N D: "Behavioral-pharmacological study of a possible analgesic effect of vigabatrin (gamma-vinil-GABA) in experimental chronic neuropathic pain", ARQUIVOS DE NEURO-PSIQUIATRIA, (MAR 1998) VOL. 56, NO. 1, PP. 150-150. PUBLISHER: ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA, C/O DR OSWALDO LANGE, CAIXA POSTAL 8877, 01065-970 SAO PAULO SP, BRAZIL. ISSN: 0004-282X., vol. 56, no. 1, March 1998 (1998-03-01), UNIV FED CEARA, TESE MESTRADO, FORTALEZA, CEARA, BRAZIL, pages 150, XP000905078 * |
BENNETT GJ, XIE JK: "A peripheral mononeuropathy in rats produces disorders of pain sensation like those seen in man", PAIN, vol. 33, 1988, pages 87 - 107, XP000905585 * |
BUCKETT W R: "THE INFLUENCE OF A GABA TRANSAMINASE INHIBITOR, GAMMA-VINYL GABA, ON VOLUNTARY MORPHINE CONSUMPTION IN THE RAT", PSYCHOPHARMACOLOGY,DE,SPRINGER VERLAG, BERLIN, vol. 75, no. 2, 1981, pages 214 - 216, XP000856589, ISSN: 0033-3158 * |
DEWEY S L ET AL: "A PHARMACOLOGIC STRATEGY FOR THE TREATMENT OF NICOTINE ADDICTION", SYNAPSE,GB,WILEY AND SONS, CHICHESTER, vol. 31, no. 1, January 1999 (1999-01-01), pages 76 - 86, XP000856613, ISSN: 0887-4476 * |
GRAM L. ET AL: "Experimental studies of the influence of vigabatrin on the GABA system.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, (1989) 27/SUPPL. 1 (13S-17S)., XP000905099 * |
MORGAN ET AL: "Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine", SYNAPSE,GB,WILEY AND SONS, CHICHESTER, vol. 18, no. 1, January 1998 (1998-01-01), pages 60 - 65, XP002127041, ISSN: 0887-4476 * |
SASTRE-GARAU P; THOMAS P; BEAUSSART M; GOUDEMAND M: "Manic attack induced by a vigabatrin-clomipramine association.", ENCEPHALE, vol. 19, no. 4, 1993, pages 351 - 352, XP000911788 * |
SHERIF FATHI M; TAWATI AHMED M; AHMED SALEEM S; SHARIF SULEIMAN I: "Basic aspects of GABA-transmission in alcoholism, with particular reference to GABA-transaminase.", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 7, no. 1, 1997, pages 1 - 7, XP000911797 * |
STUPPAECK C H ET AL: "THE IRREVERSIBLE GAMMA-AMINOBUTYRATE TRANSAMINASE INHIBITOR VIGABATRIN IN THE TREATMENT OF THE ALCOHOL WITHDRAWAL SYNDROME", ALCOHOL AND ALCOHOLISM. SUPPLEMENT,GB,PERGAMON, OXFORD, vol. 31, no. 1, January 1996 (1996-01-01), pages 109 - 111, XP000856593, ISSN: 1358-6173 * |
WEGELIUS K ET AL: "GAMMA-VINYL GABA DECREASES VOLUNTARY ALCOHOL CONSUMPTION IN ALCOHOL-PREFERRING AA RATS", PHARMACOLOGY AND TOXICOLOGY,DK,MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN,, vol. 73, no. 3, September 1993 (1993-09-01), pages 150 - 152, XP000856621, ISSN: 0901-9928 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000010554A2 (fr) | 2000-03-02 |
JP2003520189A (ja) | 2003-07-02 |
EP1107748A2 (fr) | 2001-06-20 |
AU5784499A (en) | 2000-03-14 |
CA2341400A1 (fr) | 2000-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000016762A3 (fr) | Procede pour reduire la dependance a la nicotine | |
WO2001076575A3 (fr) | Traitement de troubles respiratoires | |
NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
ZA200202521B (en) | 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preprations containing said compounds. | |
CA2239174A1 (fr) | Nouveaux composes a effet analgesique | |
AU677279B2 (en) | Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes | |
AU5716898A (en) | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease | |
CA2311356A1 (fr) | Procede pour le traitement de la maladie d'alzheimer | |
BG105096A (en) | Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders | |
AU3162001A (en) | Medicament, a method for its production and the use thereof | |
AU5489299A (en) | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine | |
WO2003072048A3 (fr) | Soulagement des symptomes des troubles gastro-intestinaux | |
AU2002307049A1 (en) | Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia | |
WO1999044608A8 (fr) | Nouvelle utilisation | |
WO2000010554A3 (fr) | Procedes et compositions employant le vigabatrin s(+) optiquement pur | |
WO2000071108A3 (fr) | Procedes de traitement de l'asthme a l'aide de s-oxybutynine | |
AU6682298A (en) | Use of r-nsaid's for the prevention of alzheimer's disease | |
WO2000051582A3 (fr) | Procedes de traitement de l'apnee et de troubles de l'apnee a l'aide de r(+) ondansetron optiquement pur | |
NZ502495A (en) | Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome | |
IL143985A0 (en) | New use of melagatran | |
WO2002011737A3 (fr) | Medicament anti-inflammatoire | |
HK1024631A1 (en) | Use of (+) mefloquine for the treatment of malaria | |
WO1997009317A3 (fr) | Derive phenylpyrimidine actif optiquement utilise en tant qu'agent analgesique | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
AU2003290015A1 (en) | Mastitis treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2341400 Country of ref document: CA Ref country code: CA Ref document number: 2341400 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 57844/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999945177 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999945177 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999945177 Country of ref document: EP |